Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial

Catheterization and Cardiovascular Interventions

Volumn 80, Issue 5, 2012, Pages 756-765

  Post, Simone ^a,b   Post, Martijn C ^a   Van Den Branden, Ben J ^a   Eefting, Frank D ^a   Goumans, Marie José ^b   Stella, Pieter R ^b   Van Es, Hendrik W ^a   Wildbergh, Thierry X ^b   Rensing, Benno J ^a   Doevendans, Pieter A ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

HMG CoA reductase inhibitors; magnetic resonance imaging; microvascular perfusion; percutaneous coronary intervention; remodeling

Indexed keywords

ATORVASTATIN; CREATINE KINASE; CREATINE KINASE MB; PLACEBO;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART FAILURE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEART VENTRICLE REMODELING; HUMAN; MALE; OUTCOME ASSESSMENT; PERCENTAGE ENHANCED AREA; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT PLANNING;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY CIRCULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMODYNAMICS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NETHERLANDS; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84867900547     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23449     Document Type: Article

References (37)

1. Sheiban I, Fragasso G, Rosano GM, Dharmadhikari A, Tzifos V, Pagnotta P, Chierchia SL, Trevi G,. Time course and determinants of left ventricular function recovery after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2001; 38: 464-471.
2. Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA,. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004; 61: 414-426.
3. Yellon DM, Hausenloy DJ,. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
4. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, ndre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M,. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-481.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
6. Bell RM, Yellon DM,. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41: 508-515.
7. Horwich TB, MacLellan WR, Fonarow GC,. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004; 43: 642-648.
8. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G,. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001; 104: 982-985.
9. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A,. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-873.
10. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A,. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006; 97: 1165-1171.
11. Eefting FD, Cramer MJ, Stella PRS, Rensing BJ, Doevendans PA,. Rationale of the REPERATOR study. Neth Heart J 2006; 14: 95-99.
12. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E,. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-888.
13. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312: 932-936.
14. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F,. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-2306.
15. Claeys MJ, Bosmans J, Veenstra L, Jorens P, De Raedt H, Vrints CJ,. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: Importance of microvascular reperfusion injury on clinical outcome. Circulation 1999; 99: 1972-1977.
16. Doevendans PA, Gorgels AP, van der Zee R, Partouns J, Bar FW, Wellens HJ,. Electrocardiographic diagnosis of reperfusion during thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1995; 75: 1206-1210.
17. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ,. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100: 178-184.
18. Chen J, Shen H, Nagasawa Y, Mitsui K, Tsurugi K, Hashimoto K,. Pravastatin inhibits arrhythmias induced by coronary artery ischemia in anesthetized rats. J Pharmacol Sci 2007; 103: 317-322.
19. Martin J, Denver R, Bailey M, Krum H,. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: Implications for ventricular remodelling. Clin Exp Pharmacol Physiol 2005; 32: 697-701.
20. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T,. HMG-CoA reductase inhibitor mobilizes bone marrow-Derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
21. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T,. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-2779.
22. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikcioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ,. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: A meta-analysis of randomized controlled trials. JAMA 2006; 295: 2046-2056.
23. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ,. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96: 611-616.
24. Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, Mehta RH, Brieger D,. Association of statin therapy with outcomes of acute coronary syndromes: The GRACE study. Ann Intern Med 2004; 140: 857-866.
25. Stenestrand U, Wallentin L,. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
26. Cahoon WD Jr, Crouch MA,. Preprocedural statin therapy in percutaneous coronary intervention. Ann Pharmacother 2007; 41: 1687-1693.
27. Kiyokuni M, Kosuge M, Ebina T, Hibi K, Tsukahara K, Okuda J, Iwahashi N, Maejima N, Kusama I, Komura N, Nakayama N, Umemura S, Kimura K,. Effects of pretreatment with statins on infarct size in patients with acute myocardial infarction who receive fibrinolytic therapy. Circ J 2009; 73: 330-335.
28. Hoffmann R, Haager P, Suliman H, Christott P, Radke P, Blindt R, Kelm M,. Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion. Am J Cardiol 2008; 101: 139-143.
29. Ishii H, Ichimiya S, Kanashiro M, Aoyama T, Ogawa Y, Murakami R, Amano T, Naruse K, Matsubara T, Murohara T,. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: A retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther 2006; 28: 1812-1819.
30. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G,. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278.
31. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ,. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90: 29-34.
32. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ,. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
33. Yuasa K, Sugimura K, Kawamitsu H, Ishida T, Shimada T, Ishibashi Y,. Quantification of occlusive and reperfused myocardial infarct size with Gd-DTPA-enhanced MR imaging. Eur J Radiol 1993; 17: 150-154.
34. Hausenloy DJ, Yellon DM,. Time to take myocardial reperfusion injury seriously. N Engl J Med 2008; 359: 518-520.
35. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM,. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
36. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL,. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996; 60: 687-695.
37. Jones SP, Gibson MF, Rimmer DM III, Gibson TM, Sharp BR, Lefer DJ,. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002; 40: 1172-1178.